Advanced Search

Oncology & Hematology Coding Alert

Correction:

Taxotere and Gleevec

Published on Sat Jan 22, 2005

The article "Injection Code Smarts Sharpen Chemo Claims" in the November 2004 issue of Oncology Coding Alert contained an example of a physician subcutaneously delivering 40 milligrams of the anti-cancer drug Taxotere. However, Taxotere cannot be delivered subcutaneously.

In the same issue, "If Diagnosis Is Already Known, Don't Report E/M Service" proffered the example of a leukemia patient who undergoes regular chemotherapy injection treatments of Gleevec. The drug Gleevec is a tablet and cannot be given via injection.
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in your eNewsletter
  • 6 annual AAPC-approved CEUs*
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more
*CEUs available with select eNewsletters.

Other Articles in this issue of

Oncology & Hematology Coding Alert

View All